Advice
following a full submission
rifaximin (Targaxan®) is accepted for use within NHS Scotland.
Indication under review: reduction in recurrence of episodes of overt hepatic encephalopathy (HE) in patients ≥18 years of age.
In a double-blind randomised controlled study of six months duration, rifaximin was superior to placebo for the primary outcome of time to first overt breakthrough episode of HE.
Download detailed advice134KB (PDF)
Medicine details
- Medicine name:
- rifaximin (Targaxan)
- SMC ID:
- 893/13
- Indication:
- Reduction in recurrence episodes of overt hepatic encephalopathy in patients 18 years or older.
- Pharmaceutical company
- Norgine Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 September 2013